Alkermes announced that the FDA has approved Aristada Initio (aripiprazole lauroxil) for the initiation of Aristada (aripiprazole lauroxil), a long-acting...
The FDA has approved Aristada (aripiprazole lauroxil), from Alkermes, an extended-release injectable suspension for the treatment of schizophrenia. Aristada is...
Alkermes announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for a two-month dosing interval...
Alkermes plc announced positive topline data from a randomized, open-label, pharmacokinetic (PK) study evaluating a two-month dosing interval of Aristada...
Alkermes announced positive topline results from the phase III ALPINE, a first-of-its-kind, six-month study evaluating the efficacy, safety and tolerability...
Alkermes plc announced that data from its phase IIIb ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness) study were published in the Journal of Clinical Psychiatry.